Profile data is unavailable for this security.
About the company
Boiron SA is a France-based pharmaceutical company engaged in the provision of homeopathic medicines. The Company develops, manufactures and markets single homeopathic medicines and drugs which are in the form of tablets, syrups, single-dose liquids and ointments. It also produces medicines based on trace elements, phytotherapy remedies, food supplements, as well as health and beauty care products. In addition, the Company owns a research center, which works for the development of homeopathy within the world of medicine. Boiron SA operates through a number of subsidiaries, which are based in Italy, Spain, Belgium, the Czech Republic, Slovakia, Russia, Romania, Poland, Hungary, the United States, Canada and Brazil, among others.
- Revenue in EUR (TTM)504.86m
- Net income in EUR19.37m
- Incorporated1967
- Employees2.74k
- LocationBoiron SA2 avenue de l ouest LyonnaisRONTALON 69510FranceFRA
- Phone+33 478456100
- Fax+33 478456291
- Websitehttps://www.boiron.fr/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai MicuRx Pharmaceutical Co Ltd | 16.67m | -41.83m | 502.61m | 188.00 | -- | 15.99 | -- | 30.15 | -0.5197 | -0.5197 | 0.2077 | 0.3929 | 0.161 | 0.4661 | 3.95 | 727,105.00 | -40.40 | -31.40 | -53.04 | -35.41 | 84.26 | 82.42 | -250.89 | -503.67 | 2.15 | -406.30 | 0.5862 | -- | 43.51 | -- | -4.65 | -- | 51.72 | -- |
| EirGenix Inc | 25.10m | -18.92m | 504.16m | 207.00 | -- | 2.16 | -- | 20.09 | -2.33 | -2.33 | 3.09 | 28.31 | 0.0884 | 1.43 | 2.48 | -- | -6.67 | -6.19 | -7.06 | -6.71 | 17.96 | 48.65 | -75.39 | -44.79 | 6.59 | -- | 0.1436 | -- | -1.34 | 16.21 | 23.70 | -- | 12.26 | -- |
| Supriya Lifescience Ltd | 68.43m | 17.24m | 509.86m | 515.00 | 29.54 | -- | 25.94 | 7.45 | 23.05 | 23.05 | 91.47 | -- | -- | -- | -- | 14,280,700.00 | -- | 18.45 | -- | 21.63 | 72.33 | 59.62 | 25.19 | 25.45 | -- | 129.43 | -- | 3.59 | 22.11 | 17.45 | 57.80 | 20.69 | 45.94 | -- |
| Shandong Boan Biotechnology Co Ltd | 92.40m | 3.91m | 519.94m | 714.00 | 121.78 | 1.93 | 36.55 | 5.63 | 0.0636 | 0.0636 | 1.51 | 4.01 | 0.2530 | 1.34 | 1.73 | 1,054,275.00 | 1.07 | -- | 1.41 | -- | 71.70 | -- | 4.23 | -- | 1.45 | 1.81 | 0.2827 | -- | 17.50 | -- | 161.31 | -- | -- | -- |
| Boiron SA | 504.86m | 19.37m | 523.73m | 2.74k | 26.76 | 1.40 | 8.54 | 1.04 | 1.12 | 1.12 | 29.08 | 21.26 | 0.9021 | 1.30 | 6.51 | 182,193.40 | 3.46 | 4.01 | 4.34 | 5.04 | 73.71 | 73.23 | 3.84 | 5.81 | 1.46 | -- | 0.0467 | 66.42 | -1.15 | -2.63 | -68.36 | -22.53 | -15.75 | 2.71 |
| Rigel Pharmaceuticals Inc | 237.67m | 95.46m | 524.88m | 162.00 | 5.56 | 5.29 | 5.38 | 2.21 | 6.17 | 6.17 | 15.36 | 6.48 | 1.48 | 2.15 | 7.37 | 1,741,210.00 | 59.33 | -16.62 | 97.15 | -28.36 | 93.10 | 95.63 | 40.17 | -16.88 | 2.14 | 25.77 | 0.3368 | -- | 53.38 | 24.77 | 169.69 | -- | -22.92 | -- |
| VIVA Biotech Holdings | 224.25m | 21.04m | 530.39m | 2.09k | 32.59 | 1.11 | 9.78 | 2.37 | 0.0709 | 0.0709 | 0.6816 | 2.09 | 0.2612 | 4.24 | 4.94 | 1,008,351.00 | 3.22 | -1.28 | 3.81 | -1.56 | 37.44 | 34.30 | 12.33 | -4.94 | 1.44 | -- | 0.2283 | -- | -7.84 | 43.80 | 244.08 | -8.85 | 27.82 | -- |
| Sinovac Biotech Ltd | 361.63m | -110.15m | 539.16m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
Data as of Feb 13 2026. Currency figures normalised to Boiron SA's reporting currency: Euro EUR
5.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Financi�re de l'�chiquier SAas of 31 Mar 2025 | 238.57k | 1.36% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 182.45k | 1.04% |
| Gay-Lussac Gestion SAas of 31 Dec 2024 | 106.00k | 0.60% |
| HMG Finance SAas of 31 Dec 2025 | 100.05k | 0.57% |
| HC Capital Advisors GmbHas of 31 Oct 2025 | 89.26k | 0.51% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 78.53k | 0.45% |
| DNCA Finance SAas of 31 Mar 2025 | 75.05k | 0.43% |
| Montaigne Capital SASas of 28 Nov 2025 | 42.87k | 0.24% |
| Amiral Gestion SAas of 31 Dec 2024 | 42.16k | 0.24% |
| Sycomore Asset Management SAas of 30 Jan 2026 | 30.12k | 0.17% |
More ▼
Data from 31 Dec 2024 - 30 Jan 2026Source: FactSet Research Systems Inc.
